Zobrazeno 1 - 10
of 20
pro vyhledávání: '"Wendy Bergmann"'
Autor:
Claudia Maletzki, Vivica Freiin Grote, Friederike Kalle, Thoralf Kleitke, Annette Zimpfer, Anne-Sophie Becker, Wendy Bergmann-Ewert, Anika Jonitz-Heincke, Rainer Bader, Brigitte Vollmar, Stephan Hackenberg, Agmal Scherzad, Robert Mlynski, Daniel Strüder
Publikováno v:
Cell Death Discovery, Vol 10, Iss 1, Pp 1-5 (2024)
Externí odkaz:
https://doaj.org/article/35f119f2837b49df836c9ac7ae854d0c
Autor:
Thomas Freitag, Philipp Kaps, Justus Ramtke, Sarah Bertels, Emily Zunke, Björn Schneider, Anne-Sophie Becker, Dirk Koczan, Daniel Dubinski, Thomas M. Freiman, Felix Wittig, Burkhard Hinz, Mike-Andrew Westhoff, Hannah Strobel, Franziska Meiners, Daniel Wolter, Nadja Engel, Sascha Troschke-Meurer, Wendy Bergmann-Ewert, Susanne Staehlke, Annabell Wolff, Florian Gessler, Christian Junghanss, Claudia Maletzki
Publikováno v:
npj Precision Oncology, Vol 8, Iss 1, Pp 1-17 (2024)
Abstract Here, we show that combined use of the EZH2 inhibitor GSK126 and the CDK4/6 inhibitor abemaciclib synergistically enhances antitumoral effects in preclinical GBM models. Dual blockade led to HIF1α upregulation and CalR translocation, accomp
Externí odkaz:
https://doaj.org/article/48c31a82a0d54c5ea79c6f99d70e3d61
Autor:
Annabell Wolff, Paula Krone, Johanna Maennicke, Julia Henne, Sonja Oehmcke-Hecht, Caterina Redwanz, Wendy Bergmann-Ewert, Christian Junghanss, Larissa Henze, Claudia Maletzki
Publikováno v:
Translational Oncology, Vol 47, Iss , Pp 102053- (2024)
Background: The CDK4/6 inhibitor abemaciclib is an FDA-approved agent and induces T-cell-mediated immunity. Previously, we confirmed the therapeutic potential of abemaciclib on mismatch repair-deficient (dMMR) tumors in mice. Here, we applied a proph
Externí odkaz:
https://doaj.org/article/eac5a1c76e4a4c1983f6fdb028e98cf2
Autor:
Annika Kayser, Annabell Wolff, Peggy Berlin, Lara Duehring, Larissa Henze, Ralf Mundkowski, Wendy Bergmann, Brigitte Müller-Hilke, Charlotte Wagner, Maja Huehns, Sonja Oehmcke-Hecht, Claudia Maletzki
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-12 (2024)
Abstract Thromboembolic events are complications in cancer patients and hypercoagulability has been linked to the tissue factor (TF) pathway, making this an attractive target. Here, we investigated the effects of chemotherapeutics and CDK inhibitors
Externí odkaz:
https://doaj.org/article/0e2a2b478c654978834942a660548817
Publikováno v:
Frontiers in Immunology, Vol 15 (2024)
BackgroundAfter licensing of the protein-based vaccine NVX-CoV2373, three technically different vaccines against the SARS-CoV-2 became available for application to the human population - and for comparison of efficacies.MethodsWe here recruited 42 st
Externí odkaz:
https://doaj.org/article/1ce225bf827240deb6bc84718f039e0b
Autor:
Claudia Maletzki, Vivica Freiin Grote, Friederike Kalle, Thoralf Kleitke, Annette Zimpfer, Anne-Sophie Becker, Wendy Bergmann-Ewert, Anika Jonitz-Heincke, Rainer Bader, Brigitte Vollmar, Stephan Hackenberg, Agmal Scherzad, Robert Mlynski, Daniel Strüder
Publikováno v:
Cell Death Discovery, Vol 9, Iss 1, Pp 1-11 (2023)
Abstract High hydrostatic pressure specifically devitalizes cells and tissues without major changes in their molecular structure. Hence, high hydrostatic pressure may enhance the development of whole-cell anti-tumor vaccines, representing tumor heter
Externí odkaz:
https://doaj.org/article/b841701ec51f4facbc107285f39da9cf
Autor:
Praveen Vasudevan, Markus Wolfien, Heiko Lemcke, Cajetan Immanuel Lang, Anna Skorska, Ralf Gaebel, Anne-Marie Galow, Dirk Koczan, Tobias Lindner, Wendy Bergmann, Brigitte Mueller-Hilke, Brigitte Vollmar, Bernd Joachim Krause, Olaf Wolkenhauer, Gustav Steinhoff, Robert David
Publikováno v:
Genome Medicine, Vol 15, Iss 1, Pp 1-18 (2023)
Abstract Background The immune response is a crucial factor for mediating the benefit of cardiac cell therapies. Our previous research showed that cardiomyocyte transplantation alters the cardiac immune response and, when combined with short-term pha
Externí odkaz:
https://doaj.org/article/c1342d67edd547f692361732bde8fead
Autor:
Michael Hecker, Brit Fitzner, Nina Boxberger, Elena Putscher, Robby Engelmann, Wendy Bergmann, Michael Müller, Isis Ludwig-Portugall, Margit Schwartz, Stefanie Meister, Ales Dudesek, Alexander Winkelmann, Dirk Koczan, Uwe Klaus Zettl
Publikováno v:
Journal of Neuroinflammation, Vol 20, Iss 1, Pp 1-18 (2023)
Abstract Background Multiple sclerosis (MS) is a chronic, inflammatory and neurodegenerative disease that leads to irreversible damage to the brain and spinal cord. The goal of so-called "immune reconstitution therapies" (IRTs) is to achieve long-ter
Externí odkaz:
https://doaj.org/article/f17f465a1e9f4f1ab39b134ac143e068
Autor:
Paula Krone, Annabell Wolff, Julia Teichmann, Johanna Maennicke, Julia Henne, Leonie Engster, Inken Salewski, Wendy Bergmann, Christian Junghanss, Claudia Maletzki
Publikováno v:
OncoImmunology, Vol 12, Iss 1 (2023)
ABSTRACTWide-spread cancer-related immunosuppression often curtails immune-mediated antitumoral responses. Immune-checkpoint inhibitors (ICIs) have become a state-of-the-art treatment modality for mismatch repair-deficient (dMMR) tumors. Still, the i
Externí odkaz:
https://doaj.org/article/74275ddb60e74d7fb08e87f87a7b42d8
Autor:
Charlotte Linke, Thomas Freitag, Christin Riess, Jana Vanessa Scheffler, Katharina del Moral, Nina Schoenwaelder, Tomas Fiedler, Adina Fiebig, Philipp Kaps, Daniel Dubinski, Björn Schneider, Wendy Bergmann, Carl Friedrich Classen, Claudia Maletzki
Publikováno v:
Cancer Cell International, Vol 23, Iss 1, Pp 1-18 (2023)
Abstract Background Arginine auxotrophy constitutes a shortcoming for ~ 30% of glioblastoma multiforme (GBM). Indeed, arginine-depleting therapy using arginine deiminase from Streptococcus pyogenes (SpyADI) has proven activity against GBM in preclini
Externí odkaz:
https://doaj.org/article/b688d5f6f21b43c69fa8ffaf7d1c4143